Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Clin Infect Dis. 2022 Jun 10;74(11):2010-2019. doi: 10.1093/cid/ciab743.
Organ transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV (HIV D+/R+) presents risks of donor-derived infections. Understanding clinical, immunologic, and virologic characteristics of HIV-positive donors is critical for safety.
We performed a prospective study of donors with HIV-positive and HIV false-positive (FP) test results within the HIV Organ Policy Equity (HOPE) Act in Action studies of HIV D+/R+ transplantation (ClinicalTrials.gov NCT02602262, NCT03500315, and NCT03734393). We compared clinical characteristics in HIV-positive versus FP donors. We measured CD4 T cells, HIV viral load (VL), drug resistance mutations (DRMs), coreceptor tropism, and serum antiretroviral therapy (ART) detection, using mass spectrometry in HIV-positive donors.
Between March 2016 and March 2020, 92 donors (58 HIV positive, 34 FP), representing 98.9% of all US HOPE donors during this period, donated 177 organs (131 kidneys and 46 livers). Each year the number of donors increased. The prevalence of hepatitis B (16% vs 0%), syphilis (16% vs 0%), and cytomegalovirus (CMV; 91% vs 58%) was higher in HIV-positive versus FP donors; the prevalences of hepatitis C viremia were similar (2% vs 6%). Most HIV-positive donors (71%) had a known HIV diagnosis, of whom 90% were prescribed ART and 68% had a VL <400 copies/mL. The median CD4 T-cell count (interquartile range) was 194/µL (77-331/µL), and the median CD4 T-cell percentage was 27.0% (16.8%-36.1%). Major HIV DRMs were detected in 42%, including nonnucleoside reverse-transcriptase inhibitors (33%), integrase strand transfer inhibitors (4%), and multiclass (13%). Serum ART was detected in 46% and matched ART by history.
The use of HIV-positive donor organs is increasing. HIV DRMs are common, yet resistance that would compromise integrase strand transfer inhibitor-based regimens is rare, which is reassuring regarding safety.
从艾滋病毒(HIV)阳性供体向 HIV 阳性(HIV D+/R+)受者移植器官存在供体源性感染的风险。了解 HIV 阳性供体的临床、免疫和病毒学特征对于确保安全至关重要。
我们在 HIV D+/R+移植的 HIV 器官政策公平(HOPE)法案行动研究中(ClinicalTrials.gov NCT02602262、NCT03500315 和 NCT03734393),对 HIV 阳性和 HIV 假阳性(FP)检测结果的供体进行了前瞻性研究。我们比较了 HIV 阳性供体与 FP 供体的临床特征。我们使用质谱法测量了 HIV 阳性供体的 CD4 T 细胞、HIV 病毒载量(VL)、耐药突变(DRMs)、核心受体嗜性和血清抗逆转录病毒治疗(ART)检测。
2016 年 3 月至 2020 年 3 月,92 名供体(58 名 HIV 阳性,34 名 FP),占该期间所有美国 HOPE 供体的 98.9%,捐献了 177 个器官(131 个肾脏和 46 个肝脏)。每年供体数量都在增加。与 FP 供体相比,HIV 阳性供体的乙型肝炎(16%对 0%)、梅毒(16%对 0%)和巨细胞病毒(CMV;91%对 58%)的患病率更高;丙型肝炎病毒血症的患病率相似(2%对 6%)。大多数 HIV 阳性供体(71%)有明确的 HIV 诊断,其中 90%接受了 ART 治疗,68%的 VL<400 拷贝/mL。中位 CD4 T 细胞计数(四分位距)为 194/µL(77-331/µL),中位 CD4 T 细胞百分比为 27.0%(16.8%-36.1%)。42%检测到主要 HIV DRMs,包括非核苷类逆转录酶抑制剂(33%)、整合酶链转移抑制剂(4%)和多类(13%)。46%检测到血清 ART,且与病史匹配的 ART 治疗。
HIV 阳性供体器官的使用正在增加。HIV DRMs 很常见,但很少有会影响基于整合酶链转移抑制剂方案的耐药性,这对于安全性来说是令人欣慰的。